The Global Telmisartan Market size is expected to reach $4 billion by 2026, rising at a market growth of 5.8% CAGR during the forecast period. Telmisartan refers to an angiotensin receptor blocker (ARB) utilized alone or combined with other agents in order to treat stroke management, cardiac arrest, and hypertension. Telmisartan is available in various generic forms and under the trade name Micardis. Telmisartan also has its side effects including cough, dizziness, sinus pain, lightheadedness, and others.
Aspects such as rising cases of high blood pressure, growing occurrences of chronic diseases like diabetes, the increasing geriatric population would boost the growth of the global telmisartan market. Moreover, a growing number of approval for abbreviated new drug applications (ANDA) for the production of generic telmisartan tablets would present new growth avenues for the global telmisartan market.
Some of the factors that are responsible for the growth of the Telmisartan market including rising cases of high blood pressure (hypertension), increasing geriatric population, and a surge in supportive government initiatives for increasing awareness about blood pressure diseases. Moreover, the telmisartan market would be supplemented by various factors such as increasing marketing approvals for generic forms of telmisartan, rising sedentary lifestyle, and rising occurrences of chronic diseases like kidney and diabetes.
The World Health Organization (WHO) on January 30, 2020, announced COVID-19 a global public health emergency. COVID-19 has severely impacted approximately 210 nations around the world. Telmisartan tablets manufacturing and distributing companies have been severely impacted by COVID-19 to a certain extent, due to the closure in several COVID-19 affected nations and a surge in the number of healthcare workers falling ill during the outbreak of the COVID-19 pandemic, resulting in the storage of supply.
Based on Indication, the market is segmented into Hypertension and Cardiovascular Risk Reduction. Currently, the hypertension segment procured the maximum revenue share of the market in 2019 and would maintain a similar trend during the forecast period. Various determinants including rising hypertension cases, surging demand for antihypertensive drugs, and increasing awareness about hypertension & its management by holding campaigns on a worldwide level would propel the growth of the segment.
Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies. On the basis of distribution channels, the market is segregated into drug stores & retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment would obtain a prominent revenue share during the forecast period owing to the increasing number of hospital pharmacies around the globe and broad-scale accessibility of hospital pharmacies. Moreover, the growth of the segment can be credited to the growing hospitalized hypertension patients & development in the structure of hospital pharmacies in developing countries like China and India.
Report Attribute | Details |
---|---|
Market size value in 2019 | USD 2.9 Billion |
Market size forecast in 2026 | USD 4 Billion |
Base Year | 2019 |
Historical Period | 2016 to 2018 |
Forecast Period | 2020 to 2026 |
Revenue Growth Rate | CAGR of 5.8% from 2020 to 2026 |
Number of Pages | 149 |
Number of Tables | 250 |
Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Companies Strategic Developments, Company Profiling |
Segments covered | Indication, Distribution Channel, Region |
Country scope | US, Canada, Mexico, Germany, UK, France, Russia, Spain, Italy, China, Japan, India, South Korea, Singapore, Malaysia, Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria |
Growth Drivers |
|
Restraints |
|
Free Valuable Insights: Global Telmisartan Market to reach a market size of $4 Billion by 2026
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America would emerge as the leading region of the global telmisartan market. It is owing to the various product launches in the U.S. For example, in July 2014, Mylan Inc., an international pharmaceutical company introduced telmisartan tablets USP, 20mg, 40mg, and 80 mg, which are the generic form of Boehringer Ingelheim’s Micardis tablets that got the final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA).
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
By Indication
By Distribution Channel
By Geography
The global telmisartan market size is expected to reach $4 billion by 2026.
The increasing number of lifestyle diseases to support the consumption are driving the market in coming years, however, Telmisartan may combine with other drugs and has some side effects have limited the growth of the market.
Yes, Telmisartan tablets manufacturing and distributing companies have been severely impacted by COVID-19 to a certain extent, due to the closure in several COVID-19 affected nations and a surge in the number of healthcare workers falling ill during the outbreak of the COVID-19 pandemic, resulting in the storage of supply.
Abbott Laboratories, Aurobindo Pharma Limited, Boehringer Ingelheim International GmbH, Cipla Limited, GlaxoSmithKline PLC (GSK), Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Cadila Healthcare Ltd. (Zydus Cadila).
The North America market dominated the Global Telmisartan Market by Region in 2019.
The Hypertension market dominated the Global Telmisartan Market by Indication in 2019, thereby, growing at a CAGR of 5.7 % during the forecast period.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.